DuChemBio

At a glance

DuChemBio filed 24 disclosures in the last 12 months, including 1 5% holder and 1 m&a. The most recent key filing was on Aug 31: A major holder's stake rose from 0.00% to 5.04% (open-market buy).

Revenue for 2025 was ₩38.6B, up 8.3% on 2024. Operating margin was 19.3% against 14.3% a year earlier. Debt was 58% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩20.9B and operating profit of ₩3.2B.

The 2025 annual report lists 144 employees with an average tenure of 4.7 years and average pay of ₩44.5M, #1971 of 2,191 listed companies by average pay. Its 4 directors and auditors were paid ₩63.2M each on average. It paid no cash dividend for 2025. (주)지오영 and related parties held 60.87% at year end.

Of 1 recent 5%+ holder report, 1 raised and 0 cut a stake; the largest stake reported was 5.04% on Aug 31.

From the 2025 annual report

Staff: 144 (115 men, 29 women), of whom 7 on fixed-term contracts. Total pay for the year: ₩6.4B. Directors and auditors: 4, paid ₩252.7M in total.

No cash dividend was paid for 2025.

Largest shareholder

(주)지오영 holds 51.55%; with 3 related parties the group holds 60.87% of common shares at year end.

Auditor: 삼정회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary

5%+ holder reports